A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Sponsor: Genentech, Inc.
You may qualify if…
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- ✓ Life expectancy \>=3 months, in the investigator's judgment
- ✓ Adequate hematologic and end-organ function
- ✓ Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care
- ✓ Measurable disease per RECIST v1.1
- ✓ Tumor specimen availability, for certain cohorts
You may not qualify if…
- ✕ Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions
- ✕ Active hepatitis B or C
- ✕ Active tuberculosis
- ✕ Positive test for human immunodeficiency virus (HIV) infection
- ✕ Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion
- ✕ Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- ✕ Active or history of autoimmune disease
- ✕ Prior allogeneic stem cell or organ transplantation
Where it's recruiting
Birmingham
New Haven
New York
Columbus
Harrisburg
Nashville
Source: ClinicalTrials.gov · NCT06031441 · last updated 2026-06-02